MYSTERIOUS: Sanofi | Mind Blowing Facts

An $8 Billion Reason Why Regeneron Stock Is in Focus

Regeneron announces an expanded deal with Sanofi. Here’s what the disclosure really means for REGN shares.

Barchart · Oct 2

3 Beaten-Down Blue-Chip Stocks to Buy Now on the Dip

With hundreds of stocks hitting new 52-week lows, contrarian stock pickers may find opportunity in PepsiCo, Sanofi and Weyerhaeuser. All three trade at deep discounts, offer high dividend yields and have catalysts for long-term recovery.

Barchart · Sep 30

Florida Sues Insulin Makers and Drug Middlemen, Alleging Pricing Deals Raised Costs for Residents Who Rely on Insulin

Florida's attorney general alleges insulin makers and PBMs inflated the list prices that many patients pay. What the lawsuit claims and how to cut costs.

Medical Daily · Sep 25

Europe depends on China. Here's where China still depends on Europe — more than you'd think

While Europe's dependence on China is widely recognized, China's reliance on the EU in key technologies is often overlooked. Despite its push for technological self-reliance, Beijing still depends on European capabilities in critical areas.

Euronews · Jun 29

June Brought Two Major FDA Advances for Children with Type 1 Diabetes: Here's What Each One Does

June 2026 brought two FDA milestones for pediatric diabetes: an OTC kids' CGM and teplizumab for Stage 3 Type 1 diabetes in ages 8–17. Here's what each one does and who qualifies.

Medical Daily · Jun 28

Drug that delays onset of type 1 diabetes approved in England and Wales

Availability of teplizumab on the NHS – which postpones early stages of disease for up to three years – described as an ‘incredible moment’

The Guardian - UK · Jun 23

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

The Economic Times · Jun 15

Sanofi is building its own AI ecosystem to give the French pharma giant an edge

Sanofi is developing custom tools and reimagining AI workflows, rather than rely on agentic products sold by SaaS vendors.

Fortune · May 27

Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data

Kymera Therapeutics (NASDAQ:KYMR) executives said the company remains on track with key clinical timelines for its lead degrader programs, including KT-621 in atopic dermatitis and asthma, while preparing to share additional data from its IRF5 program later this year. Speaking at an RBC Capital Mar

MarketBeat · May 26

Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer

Adagene (NASDAQ:ADAG) Chief Strategy Officer Mickael Chane-Du outlined the company’s clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company’s focus on improving the therapeutic index of CTLA-4 inhibition

MarketBeat · May 19